Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy

BACKGROUND: Extended‐duration betrixaban showed a significant reduction in venous thromboembolism in the APEX trial (Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study). Given the variable clinical impact of different efficacy and safety events, one approach to assess net cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibson, C. Michael, Korjian, Serge, Chi, Gerald, Daaboul, Yazan, Jain, Purva, Arbetter, Douglas, Goldhaber, Samuel Z., Hull, Russel, Hernandez, Adrian F., Lopes, Renato D., Gold, Alex, Cohen, Alexander T., Harrington, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586307/
https://www.ncbi.nlm.nih.gov/pubmed/28698258
http://dx.doi.org/10.1161/JAHA.117.006015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586307/
https://www.ncbi.nlm.nih.gov/pubmed/28698258
http://dx.doi.org/10.1161/JAHA.117.006015

Ejemplares similares